Curtis Hughesman

This memo is to tell you about upcoming changes to how results of mainstreamed genetic testing will be
shared with ordering clinicians and patients from the Cancer Genetics and Genomics Laboratory (CGL)
and the Hereditary Cancer Program (HCP).

Effective April 1, 2023 the Cancer Genetics and Genomics Laboratory at BC Cancer will start accepting early stage (IB to IIIA) non-small cell lung cancer (adenocarcinoma) for Illumina Focus Panel NGS testing. Additional details are provided in the memo below:

The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering DPYD testing for the entire province effective March 1, 2023. DPYD screening is recommended for patients whose treatment plans include 5-fluorouracil (5FU) or capecitabine. Additional details regarding this new test can be found in the memo

This is an update to physicians who frequently order Oncopanel tumour testing through the Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer. As of July 1, 2022, germline confirmation can be ordered by any physician involved in a patient’s oncology care. Additional details are provided in the following memo.

The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will begin offering minimal/measurable residual disease (MRD) testing for select patients with Acute Myeloid Leukemia (AML) starting the week of April 11, 2022. Key points regarding this new testing are outlined in the memo below.

The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer will be commencing panel-based next generation sequencing (NGS) or “Focus Panel” testing starting May 2021. The AmpliSeq for Illumina Focus Panel enables rapid and accurate assessment of genomic variants in 52 genes with known clinical relevance in solid tumors. Additional details of the test and indications that qualify for this testing can be found in the memo below.

The Cancer Genetics and Genomics Laboratory is offering a new test that interrogates the myeloid differentiation primary response 88 (MYD88) gene to detect the L265P mutation.  MYD88 L265P is identified in approximately 90% of confirmed lymphoplasmacytic lymphoma (LPL) cases and therefore increases the likelihood for a MYD88 related LPL diagnosis. Additional details of the test can be found in the memo below.

The Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer has improved testing for clinically relevant variants in the Fms-related tyrosine kinase 3 gene (FLT3). Further details on the changes to testing can be found in the memo below.

The Cancer Genetics and Genomics Laboratory’s (CGL) at BC Cancer has developed a new more sensitive test for detection of the KIT D816V and D816F mutations. Additional details on how the test has changed can be found in the below memo.